Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Total Liabilities (2022 - 2025)

Historic Total Liabilities for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $2.6 million.

  • bioAffinity Technologies' Total Liabilities fell 2293.27% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 2293.27%. This contributed to the annual value of $3.9 million for FY2024, which is 1619.98% up from last year.
  • Per bioAffinity Technologies' latest filing, its Total Liabilities stood at $2.6 million for Q3 2025, which was down 2293.27% from $6.9 million recorded in Q2 2025.
  • bioAffinity Technologies' Total Liabilities' 5-year high stood at $6.9 million during Q2 2025, with a 5-year trough of $775151.0 in Q2 2023.
  • Its 4-year average for Total Liabilities is $2.9 million, with a median of $3.2 million in 2023.
  • Its Total Liabilities has fluctuated over the past 5 years, first soared by 31583.3% in 2024, then crashed by 2293.27% in 2025.
  • bioAffinity Technologies' Total Liabilities (Quarter) stood at $1.1 million in 2022, then surged by 195.63% to $3.4 million in 2023, then rose by 16.2% to $3.9 million in 2024, then tumbled by 32.4% to $2.6 million in 2025.
  • Its Total Liabilities stands at $2.6 million for Q3 2025, versus $6.9 million for Q2 2025 and $4.1 million for Q1 2025.